🩺 Article 1: Managing Side Effects of Aspergillosis Treatments

Subtitle: What to expect, how to recognise problems early, and when to ask for help.

💊 Why This Matters

People living with aspergillosis, bronchiectasis, or Primary Ciliary Dyskinesia (PCD) often take several medicines for months or even years.
These drugs are vital for controlling infection, inflammation, and allergic reactions — but they can also cause side effects or drug interactions.

Being aware of what’s normal, what’s not, and when to seek help helps you stay safe while getting the most from treatment.

⚗️ Antifungal Medicines

Antifungal (azole) drugs are the backbone of treatment for Chronic Pulmonary Aspergillosis (CPA) and Allergic Bronchopulmonary Aspergillosis (ABPA).
They control infection but can affect the liver, heart, or skin, so regular blood monitoring is essential.

Itraconazole (SporanoxÂŽ / generic)

Used for long-term control in CPA and ABPA.

  • Common: tiredness, nausea, ankle swelling, blurred vision.

  • Serious: yellowing skin/eyes, dark urine, shortness of breath.

  • Tips:

    • Take with a main meal or fizzy drink (acidic stomach aids absorption).

    • Avoid taking it with omeprazole or similar acid-reducing drugs, as these block absorption.

    • Have regular liver-function and drug-level blood tests.

    • Report ankle swelling or jaundice immediately.

Voriconazole (VfendÂŽ)

Used when itraconazole isn’t effective or tolerated.

  • Common: temporary visual flashes or blurred vision, sunlight sensitivity, mild headache.

  • Serious: severe rash, blistering, or long-term skin-cancer risk from sunlight.

  • Tips:

    • Always use SPF 30+ sun cream, even in winter.

    • Avoid prolonged sun exposure.

    • Report any visual change, rash, or fatigue promptly.

    • Blood monitoring checks for safe drug levels.

Posaconazole (NoxafilÂŽ)

Used for resistant infections or as a second-line therapy.

  • Common: nausea, diarrhoea, fatigue.

  • Serious: liver inflammation, low potassium (causing muscle cramps or irregular heartbeat).

  • Tips:

    • Take with a main meal or full-fat snack.

    • Report unexplained muscle weakness or palpitations.

    • Keep up with blood tests.

Isavuconazole (CresembaÂŽ)

A newer antifungal option that may cause fewer interactions.

  • Common: headache, mild nausea, ankle swelling.

  • Tips:

    • Continue regular liver and kidney checks.

    • Report any new swelling, fatigue, or breathlessness.

💨 Corticosteroids

(Prednisolone, Methylprednisolone, Hydrocortisone)
These reduce inflammation and allergic response in ABPA and asthma.
They are powerful — but long-term use can affect weight, mood, bones, and hormone balance.

  • Common: increased appetite, fluid retention, mood swings, difficulty sleeping.

  • Long-term: thinning bones, higher blood sugar, adrenal suppression.

  • Tips:

    • Never stop suddenly — always taper under medical advice.

    • Carry a Steroid Emergency Card.

    • Ask about bone protection (vitamin D, calcium, bisphosphonates).

    • See your GP if you feel very tired, dizzy, or unwell.

🧬 Biologic Treatments

(Mepolizumab, Benralizumab, Omalizumab)
These injection-based medicines target inflammation or allergic responses in severe asthma or ABPA.

  • Common: mild injection-site soreness, tiredness, headache.

  • Occasional: mild fever or muscle aches.

  • Serious: allergic swelling of lips, tongue, or throat.

  • Tips:

    • Record any mild reactions.

    • If you develop swelling or difficulty breathing, call 999 immediately.

💊 Long-Term Antibiotics

(Azithromycin, inhaled colomycin, tobramycin)
Used to reduce bacterial infections in bronchiectasis or PCD.

  • Common: stomach upset, diarrhoea, mild throat irritation.

  • Long-term: tinnitus or hearing loss (especially with azithromycin).

  • Tips:

    • Have periodic hearing checks.

    • Rinse mouth and nebuliser after inhaled antibiotics.

    • Report ringing in the ears, severe diarrhoea, or rash.

⚠️ Drug Interactions

Antifungal medicines (especially azoles) can interfere with many common drugs, including:

  • Steroids (e.g., prednisolone, fluticasone) — may increase steroid levels.

  • Reflux medicines (e.g., omeprazole, lansoprazole) — reduce antifungal absorption.

  • Statins and warfarin — increase risk of side effects or bleeding.

  • Some antihistamines and antibiotics — can affect heart rhythm.

These interactions can be complex — always check before starting or stopping any medication.

✅ Check it yourself:
You can use the official BNF Interactions Checker (NICE Medicines Guidance) to see if two medicines are known to interact.
Simply type the names (e.g., itraconazole and prednisolone) and it will show the risk level, what the interaction does, and what clinicians usually recommend.
If unsure, show the result to your GP, pharmacist, or hospital team — they can interpret it for your situation.

🚨 When to Seek Help

Call your specialist or GP urgently if you notice:

  • Yellowing of skin or eyes

  • Severe rash, blistering, or peeling

  • New ankle swelling or breathlessness

  • Sudden fatigue or dark urine

  • Visual changes or increased photosensitivity

  • Ringing in the ears or hearing loss

If you feel acutely unwell, do not stop your medication abruptly — contact your hospital team or emergency services.

🔗 Next read: Why Awareness Matters – Staying Safe and Confident on Aspergillosis Treatment »

by GAtherton

⚠️ Omeprazole and PPIs: What’s Behind the Recent Warning?

Recently, several newspapers – including The Mirror – reported that a “BBC doctor” had issued a warning to anyone taking omeprazole, a commonly prescribed drug for acid reflux and heartburn.
So, is this something new, or just another media scare? Let’s look at what the evidence actually says – and what it means if you’re living with aspergillosis, bronchiectasis, or other chronic lung diseases.

💊 What Are PPIs?

Proton Pump Inhibitors (PPIs) such as omeprazole, lansoprazole, and esomeprazole are medicines that reduce stomach acid.
They’re often used to:

  • Treat reflux, indigestion, or stomach ulcers

  • Protect the stomach from irritation caused by anti-inflammatory drugs or steroids

They’re very effective and widely prescribed — millions of people in the UK take them every day.

⚠️ Why the Headlines?

The recent news stories stem from a discussion on BBC Morning Live, where GP Dr Punam Krishan highlighted the potential long-term side effects of PPIs.
Although these aren’t “new discoveries”, they serve as an important reminder that long-term PPI use should be reviewed regularly.

🧠 What the Evidence Shows

Research over the past decade has shown that taking PPIs for a long time or at high doses can lead to several possible side effects:

Possible Issue What Happens Why It Matters
Infections Higher risk of gut infections such as Clostridioides difficile and bacterial overgrowth Stomach acid normally helps kill harmful bacteria; reducing it alters the balance
Changes in gut microbiome Loss of protective “friendly” bacteria May influence digestion, immunity, and inflammation
Reduced absorption of nutrients Low magnesium, iron, or vitamin B12 Can lead to tiredness, cramps, or anaemia
Bone health Slightly higher risk of fractures with very long-term use May relate to calcium absorption
Kidney and heart effects (rare) Observed in some studies Still being researched

Most of these risks are small, and for many people the benefits outweigh them — but it’s still important to make sure you’re taking the lowest effective dose and that your doctor reviews the need for it periodically.

🫁 Why It Matters for Aspergillosis and Lung Conditions

If you have aspergillosis, bronchiectasis, or Primary Ciliary Dyskinesia (PCD), there are extra reasons to think carefully about long-term PPI use:

  • Microbiome connections: The gut and lungs are linked through what’s called the gut–lung axis. Disturbances in gut bacteria can affect immune responses elsewhere in the body — possibly including the lungs.

  • Infection control: PPIs can slightly increase the risk of bacterial or fungal overgrowth in the gut. While this doesn’t directly cause lung infection, it may influence the body’s balance between helpful and harmful microbes.

  • Medication interactions: Some antifungal medicines (like itraconazole or posaconazole) rely on stomach acidity for absorption — so PPIs can reduce their effectiveness. Your specialist will usually time doses or adjust medication accordingly.

  • Reflux and aspiration: On the other hand, reflux itself can worsen lung disease if acid is inhaled into the lungs — so stopping PPIs suddenly can make things worse. Always discuss any change with your doctor first.

🩺 What You Can Do

If you take omeprazole or another PPI:

  1. Check why you’re on it – Is it for reflux, ulcer protection, or another reason?

  2. Review the dose and duration – Many people can step down to a lower dose or switch to on-demand use once symptoms are controlled.

  3. Don’t stop suddenly – Stopping PPIs abruptly can cause a rebound in acid production and make symptoms flare.

  4. Ask about alternatives – Some people can switch to H2-blockers (e.g. ranitidine-type medicines), or use lifestyle changes such as avoiding late meals, raising the bedhead, and reducing caffeine or alcohol.

  5. Discuss with your specialist team – Particularly if you’re also on antifungal or antibiotic treatments, as interactions can occur.

🧩 Key Takeaway

The recent headlines about omeprazole are not new, but they highlight a genuine issue:
PPIs are very useful drugs — but long-term use should always be reviewed to make sure the benefits outweigh the risks.

For most people, there’s no need to panic.
Just make sure you:

  • Use the lowest effective dose

  • Review your need for PPIs at least once a year

  • Discuss any concerns with your respiratory or gastroenterology team

🔗 Useful References

by GAtherton

🧬 From Scottish Discovery to American Pharmacy Shelf: The Story of Brensocatib

Sometimes a medicine begins life in one country but reaches patients first in another. The new bronchiectasis drug brensocatib is a perfect example — discovered in Scotland, yet first approved for use in the United States.
Here’s how that happens, and what it tells us about how new treatments make their way to patients.

1️⃣ Discovery in Dundee

At the University of Dundee, scientists in the Drug Discovery Unit (DDU) were studying how certain white blood cells called neutrophils can cause long-term lung damage.
They identified an enzyme, DPP1 (dipeptidyl peptidase I), that activates destructive substances inside these cells.
Blocking DPP1 could calm inflammation without wiping out the body’s defences.
Their research produced a promising new compound — later named brensocatib — which safely switched off this process in lab studies.

2️⃣ Partnering to Go Global

Turning an early discovery into a medicine is an enormous task.
It costs hundreds of millions of pounds and can take 10–15 years.
The Dundee team partnered with Insmed, a biotechnology company based in New Jersey, USA, which had the funding and international trial experience to move brensocatib into large clinical studies.

3️⃣ Worldwide Trials

Insmed led major trials involving hundreds of people with non-cystic fibrosis bronchiectasis in hospitals across North America, Europe, and Asia.
Results showed that brensocatib reduced flare-ups and improved quality of life.
Because Insmed’s main offices and regulatory team are in the U.S., they submitted their results first to the U.S. Food and Drug Administration (FDA).

4️⃣ U.S. Approval

In 2025, the FDA approved brensocatib — the first drug of its kind to treat bronchiectasis.
American patients can now access it while other countries complete their reviews.

5️⃣ What Happens Next in the UK

In the UK, every new medicine goes through two steps:

  • The Medicines and Healthcare products Regulatory Agency (MHRA) checks that it is safe and effective.

  • Then NICE (the National Institute for Health and Care Excellence) reviews how well it works for its cost and decides whether the NHS should fund it.

NICE is expected to make its decision on brensocatib in July 2026.
Even if approved, it may first be offered to those with the most severe or frequent flare-ups while more real-world data are gathered.

💷 What Dundee Gained from Its Discovery

Although Dundee handed over development to a U.S. company, the university continues to benefit in several ways:

  • Financial return: Dundee receives upfront payments, milestone fees for each stage of progress, and royalties on global sales.
    These funds support new drug discovery projects, student training, and research facilities.

  • Scientific impact: Brensocatib’s success highlights the strength of the Drug Discovery Unit’s model, showing that UK universities can produce world-class medicines.

  • Future partnerships: Dundee’s achievement attracts new collaborations and investment, ensuring that more early discoveries have a route to reach patients.

So while the drug is made and sold by Insmed, Dundee’s scientists — and their reinvested funding — continue to play a role in future breakthroughs.

🏭 Manufacturing: Turning Discovery into a Real Medicine

Once a new drug is approved, it still has to be produced safely, at scale, and consistently.
This is often a completely separate operation from the research or licensing stage.

For brensocatib, the chemical process that makes the active ingredient was developed by Dundee and Insmed scientists early on, but large-scale manufacturing is now carried out by specialist pharmaceutical plants under strict international standards known as Good Manufacturing Practice (GMP).

Because brensocatib is a small-molecule oral drug (a tablet, not an injection), it’s made in high-tech chemical manufacturing facilities, not hospitals or biologics plants.
These sites are often in Europe, the U.S., or Asia, depending on where the supply chains, raw materials, and quality-control systems are strongest.

Manufacturing is expensive — it must ensure every tablet is identical in purity, strength, and safety — but it’s also where economies of scale help keep the cost manageable once global production ramps up.

For the NHS and NICE, manufacturing details matter too, because:

  • They affect cost-effectiveness (how much the NHS will pay per course of treatment).

  • They influence availability — whether the company can supply enough medicine to meet demand once approved in the UK.

So, while the discovery began in Dundee and the approval started in the U.S., manufacturing is the bridge that makes it real — transforming a scientific idea into a medicine that can be prescribed to patients worldwide.

🌍 Why This Matters

This journey shows how scientific discovery is global.
A breakthrough can start in a Scottish laboratory, be developed with American funding, tested around the world, manufactured across several continents, and eventually come back to help patients in the UK.
It’s a reminder that international collaboration — between researchers, funders, manufacturers, and regulators — is what turns good science into real treatments.

by GAtherton

🌿 Will My Body Start Making Cortisol Again After Long-Term Prednisolone?

Many people with Allergic Bronchopulmonary Aspergillosis (ABPA) take prednisolone (a corticosteroid) for long periods to control inflammation and prevent flare-ups.
A common concern is whether the body will ever start producing its own natural steroid hormone, cortisol, again after so many years of treatment.

💡 Why Cortisol Matters

Cortisol is a vital hormone made by your adrenal glands.
It helps your body manage stress, maintain healthy blood pressure, control inflammation, and balance energy levels.
Your brain normally regulates this through the HPA axis (Hypothalamus–Pituitary–Adrenal axis).

When you take prednisolone, your body senses there’s already enough steroid circulating, so your brain switches off the signal that tells the adrenals to make cortisol.
Over time, the adrenal glands can “go to sleep”.

⏳ After Long-Term Prednisolone Use

If you’ve taken prednisolone for months or years, your adrenal glands may not restart immediately — and sometimes not completely.
Recovery depends on several factors:

Factor How It Affects Recovery
Length of treatment The longer you’ve been on steroids, the slower recovery tends to be
Average daily dose Higher doses suppress the adrenal glands more strongly
Tapering speed A gradual, careful reduction helps the adrenals “wake up” again
Individual differences Some people recover in months, others may need lifelong steroid replacement (hydrocortisone tablets)

📅 What to Expect

  • After short courses (a few weeks), cortisol production usually returns quickly.

  • After many months or years, recovery can take months or even years.

  • Some people never regain full adrenal function and need lifelong replacement therapy.

Your specialist will usually assume your adrenal glands are suppressed until tests prove otherwise.

⚠️ Why Adrenal Suppression Is a Safety Concern

If your adrenal glands are not producing cortisol and you suddenly stop prednisolone, or become ill, have an accident, or need surgery, your body can’t produce the extra steroid it needs to handle stress.
This can cause a serious medical emergency called adrenal crisis, which may lead to low blood pressure, collapse, or shock if untreated.

That’s why it’s vital to:

  • Carry a Steroid Emergency Card or Medical Alert bracelet at all times

  • Tell healthcare staff (doctors, dentists, pharmacists, A&E teams) that you’re on or recently stopped steroids

  • Never miss a dose and never stop suddenly without medical advice

  • Use “stress-dose” steroids during illness, surgery, or injury as advised by your doctor

These simple precautions can be life-saving if your body can’t make enough cortisol during stress.

💨 What About Inhaled Steroids?

Many people with ABPA or asthma also use inhaled corticosteroids (such as fluticasone, budesonide, or beclometasone) in combination inhalers like Seretide, Symbicort, or Fostair.
These medicines mainly act in the lungs and only a small amount enters the bloodstream — but at high doses or with long-term use, they can still partly suppress the adrenal glands, especially when combined with oral steroids or certain antifungal medications.

Adrenal suppression is more likely if:

  • You use high-dose inhaled steroids for many months or years (e.g. fluticasone >500 Âľg/day)

  • You also take oral steroids (even at low doses)

  • You’re on antifungal medicines such as itraconazole, voriconazole, or posaconazole, which slow steroid breakdown

  • You are particularly sensitive to steroid effects

If suppression occurs, you might feel unusually tired, dizzy, or weak — especially when unwell or under stress.

Your doctor may test your morning cortisol or do a Synacthen test if there’s any concern.
In some cases, patients on high-dose inhaled therapy are also advised to carry a steroid card for safety, just like those on oral steroids.

The good news is that inhaled steroids are much safer than long-term oral prednisolone, and the risk of serious adrenal problems remains low when used correctly.

🧪 How Doctors Check for Recovery

Your respiratory or endocrine team may arrange:

  • Morning cortisol blood test (before your usual dose)

  • ACTH stimulation test (Synacthen test) – to see how well your adrenal glands respond

These tests help guide your doctors in determining whether your body is producing enough cortisol naturally or if you require a maintenance or replacement dose.

💊 Why Some Patients Move from Prednisolone to Hydrocortisone

If you’ve been on long-term prednisolone and your body is no longer making enough cortisol, your doctor may switch you to hydrocortisone.
Hydrocortisone is almost identical to the natural cortisol your body should produce.

Feature Prednisolone Hydrocortisone
Strength 4–5 times stronger than cortisol Matches the body’s natural cortisol
Duration of action Long-acting (12–36 hours) Short-acting (6–8 hours)
Typical use Controls inflammation during flares Replaces missing cortisol when adrenals are suppressed

Hydrocortisone is used as replacement therapy, not as an anti-inflammatory drug.
It’s given when your adrenal glands are “asleep” after long-term steroid use — or permanently if they no longer recover.

Doctors may switch to hydrocortisone if:

  • Tests show adrenal suppression (low morning cortisol or poor Synacthen test results)

  • You’ve finished tapering off prednisolone, but still feel unwell or fatigued

  • You have symptoms of adrenal insufficiency, such as dizziness, nausea, or low blood pressure

  • You need more precise stress dosing during illness or surgery

Hydrocortisone more closely mimics the body’s natural rhythm, usually taken two or three times a day, with an increased dose during illness or stress.

If you’re on hydrocortisone:

  • Carry a Steroid Emergency Card and make sure it’s visible to healthcare staff.

  • Never stop suddenly.

  • Increase (“double”) your dose when you’re ill or having surgery, as advised by your doctor.

  • Seek urgent medical help if you vomit and can’t keep tablets down — you may need an injection.

For many ABPA patients, hydrocortisone is temporary, helping to support the body until natural cortisol production recovers.
In others, especially after many years of prednisolone, it may become a lifelong replacement, which is safe and well managed under specialist supervision.

💉 The Future: Reducing Dependence on Prednisolone

The good news is that newer treatments called biologics are changing how ABPA is managed.
Biologics such as mepolizumab, benralizumab, dupilumab, and omalizumab target specific immune pathways involved in ABPA rather than suppressing the whole immune system.

For many patients, biologics:

  • Reduce or replace the need for long-term steroids

  • Lower the risk of adrenal suppression

  • Control symptoms more precisely, with fewer side effects

This means more people with ABPA may, in the future, safely taper off prednisolone and give their adrenal glands a chance to recover — always under close medical supervision.

🌤️ In Summary

After many years on prednisolone for ABPA, some people’s adrenal glands do recover, while others remain partially or fully dependent on replacement steroids.
Recovery is slow, varies between individuals, and must be guided by your specialist.
Be aware that both oral and inhaled steroids can suppress the adrenals if used long-term or at high doses.
Carrying a steroid emergency card and knowing what to do in an emergency is essential for safety — especially while your adrenals are still “waking up.”
With newer treatments like biologics and careful follow-up, the goal is to reduce steroid dependence and protect your long-term health.

by GAtherton

🌬️ Inhaled Antifungal Treatments for Chronic Pulmonary Aspergillosis (CPA)

Updated: October 2025

💡 Why are inhaled antifungals being developed?

For people living with Chronic Pulmonary Aspergillosis (CPA), treatment usually involves long courses of oral antifungal tablets such as itraconazole, voriconazole, or posaconazole.
These medicines circulate through the whole body to reach the lungs — but sometimes they cause side-effects, interact with other drugs, or fail to reach high enough levels in thick mucus, cavities, or scarred areas of lung tissue.

Inhaled antifungal therapy aims to solve this problem by delivering medicine directly to the lungs using a nebuliser or inhaler device.
This can potentially mean:

  • ✅ Higher drug levels exactly where infection is active

  • ⚡ Faster local action

  • 🚫 Fewer whole-body side-effects

  • 🧩 Fewer drug interactions

This approach is especially promising for patients with localized lung disease, such as CPA or aspergillus bronchitis, where the fungus lives in damaged parts of the lung.

💊 Current inhaled antifungal options (used off-label)

🧪 Nebulised Amphotericin B

At the moment, nebulised amphotericin B is the only inhaled antifungal used in hospitals, although it is off-label for CPA.

It is more commonly used to prevent infection in people who have had a lung transplant or who are severely immunocompromised.
In some specialist centres, it may be used as maintenance therapy or an add-on for CPA if other antifungals have not worked or cannot be tolerated.

Advantages

  • High concentration in lung tissue

  • Minimal effects on other organs (especially the kidneys)

Drawbacks

  • Possible airway irritation (cough, tight chest, wheezing)

  • Requires specialist supervision and appropriate nebuliser equipment

🔬 New treatments in development

💨 Opelconazole (also called PC-945)

Opelconazole is a new inhaled triazole antifungal developed by Pulmocide Ltd in the UK.
It works in the same way as existing azole antifungals — by blocking the fungal enzyme CYP51 — but has been specially designed to stay in the lungs and minimise side-effects elsewhere.

In laboratory and early human studies, opelconazole has shown:

  • Strong activity against Aspergillus fumigatus

  • High and lasting drug levels in the lungs

  • Very low blood levels (reducing risk of toxicity and drug interactions)

  • Good tolerability in early trials

Although not yet licensed, it has been used compassionately in small numbers of patients with difficult-to-treat lung aspergillosis at centres such as Manchester and London.

🧾 Current and recent clinical trials

Trial ID Treatment Condition Purpose / Summary Status
NCT06447402 Nebulised Amphotericin B vs Saline Chronic Pulmonary Aspergillosis Tests whether regular nebulised amphotericin can help prevent CPA relapse compared with saline. Recruiting
NCT03656081 Itraconazole ± Nebulised Liposomal Amphotericin B CPA Compares oral itraconazole alone versus itraconazole plus inhaled amphotericin for symptom and scan improvement. Completed – results pending
NCT05238116 Inhaled Opelconazole + Standard Therapy Refractory Invasive Pulmonary Aspergillosis Phase 3 trial evaluating safety and added benefit of inhaled opelconazole. UK, EU, and US sites. Recruiting
NCT05037851 Inhaled Opelconazole (PC-945) Post-Lung Transplant Prophylaxis Assesses prevention of fungal infection after transplant. Found well tolerated. Completed
PubMed 34058036 Nebulised Amphotericin B vs Oral Itraconazole Pulmonary Aspergilloma (CPA subset) Six-month open study found similar improvement rates between inhaled amphotericin and oral itraconazole. Completed

👉 You can look up any of these studies on ClinicalTrials.gov by entering the trial ID (e.g. NCT06447402).

⚠️ Things to keep in mind

  • Not yet routine — Inhaled antifungals are available only in research or specialist centres.

  • Limited evidence — Most data come from transplant or invasive aspergillosis studies, not chronic infection.

  • Delivery challenges — Damaged or scarred areas of lung may be hard for inhaled drugs to reach.

  • Possible side-effects — Coughing or mild bronchospasm are common; pre-treatment with an inhaler may help.

  • Monitoring still needed — Even with inhaled therapy, your care team will continue to check symptoms, lung scans, and blood markers (such as Aspergillus IgG).

🧭 Questions to ask your specialist

If you are interested in this type of therapy, you could ask:

  • Does my centre offer nebulised amphotericin as part of CPA care?

  • Are there any clinical trials nearby (for example NCT06447402 or NCT05238116)?

  • Could an inhaled antifungal be used with my current oral treatment?

  • What are the side-effects and how are they monitored?

  • What nebuliser device is required and how often would I use it?

🏥 UK research centres involved

Current UK involvement is mainly through:

  • National Aspergillosis Centre, Wythenshawe Hospital (Manchester)

  • Royal Brompton and Harefield Hospitals (London)

  • UK transplant centres participating in Pulmocide’s opelconazole studies

🗝️ Key takeaway

Inhaled antifungal medicines are an exciting development that could make CPA treatment safer and more targeted in the future.
For now, they are mainly available through clinical trials or specialist centres, but the early results are promising — especially for those who have struggled with oral antifungal side-effects or limited success.

If you’re interested, speak to your CPA specialist or the National Aspergillosis Centre team about ongoing research and eligibility.

by GAtherton

Damp, Mould and Health: Be Careful About Unvalidated Tests and “Detox” Treatments

Updated 2025 – by the NAC CARES team

When you’re desperate for answers

If you live in a damp or mouldy home and your health has suffered, it’s natural to want clear answers. Many people experience coughing, fatigue, sinus trouble or breathing problems and wonder if mould exposure could be the cause.

Unfortunately, the internet is full of misleading claims about “toxic mould”, “biotoxin illness”, or “mould detox”. Some websites and private clinics sell unvalidated medical tests or promote expensive supplements claiming to “flush mould toxins” or “reverse mould illness”.

People often turn to these options out of frustration and desperation when they feel ignored or dismissed by health or housing services. But it’s important to know that these tests and products are not scientifically proven — and in some cases, they may cause harm.

The truth about “mould illness” testing

At present, there is no validated medical test that can prove a person is ill because of mould exposure in their home.

Tests often sold online or through private clinics — such as urine mycotoxin tests, mould antibody panels, or chronic inflammatory response syndrome (CIRS) profiles — are not recognised by the NHS, NICE, or the World Health Organization.

These tests may detect trace amounts of mould-related compounds that appear even in healthy people. There are no agreed normal or abnormal levels, and results can vary dramatically between labs. This means a “positive” test result does not prove illness or guide treatment.

When functional, integrative, or alternative practitioners use these tests

It’s not just online sellers. Some functional medicine, integrative health, or alternative practitioners — including some with medical or allied health qualifications — also use these same mould or mycotoxin tests in private practice.

They may genuinely want to help and believe in “root cause medicine,” but:

  • Many of these tests have never been validated in peer-reviewed clinical studies.

  • Their results cannot reliably distinguish between normal environmental exposure to fungi and actual infection or allergy.

  • People are sometimes told they have “mould toxicity” or “mycotoxin poisoning” without any scientific evidence.

Why this matters

  • It can lead to unnecessary fear and anxiety.

  • Patients may spend hundreds or thousands of pounds on testing, supplements, or “detox” treatments that do not work.

  • Most importantly, genuine medical conditions — like aspergillosis, asthma, or COPD — may be diagnosed late or missed entirely.

Even if the practitioner sounds credible, unvalidated tests remain unvalidated.
If it isn’t approved by NICE, the NHS, or recognised respiratory specialists, it isn’t a reliable diagnostic test.

The risks of “detox” and self-treatment

Many websites and practitioners also recommend “detox” products such as activated charcoal, bentonite clay, chlorella, ozone therapy, or special anti-fungal diets. None of these have been proven to remove mould or mycotoxins from the body.

Some are unsafe or can interact dangerously with prescribed medicines — especially antifungal or steroid treatments used for aspergillosis. Others can damage the gut, lungs or kidneys.

No supplement, spray, or air treatment can replace medical therapy or proper repair of damp housing.

Why these products are still allowed to be sold

These tests and supplements often remain on sale because of regulatory loopholes:

  • They’re marketed as “wellness” or “informational” tests rather than diagnostic tools.

  • Supplements are classed as foods, not medicines — they must be safe, but not proven effective.

  • Many sellers are based overseas, outside UK or EU enforcement.

That’s why public awareness is crucial. Legal does not mean scientifically valid.

If you see misleading health claims, you can report them to:

What is proven to help

Here’s what current evidence supports:

  • Talk to your NHS doctor or respiratory specialist. They can arrange validated tests for fungal disease and lung health.

  • Fix the source of damp or mould. That’s the key to protecting your health — not detox kits.

  • Seek help early from housing officers, environmental health, or Citizens Advice if your home is unsafe.

  • Work with your care team — they can support housing letters or referrals if damp is affecting your condition.

See our practical guides:

If you feel dismissed or desperate

You’re not alone. Many people living in damp conditions feel frustrated and unheard. But unvalidated tests and detox programmes will not provide the answers you deserve.
You will get more meaningful, safer support through:

🛡️ Why We Take a Cautious Approach

Some people wonder whether organisations like ours are “allied to big pharma” or dismiss alternative approaches because of financial or legal pressures.

The truth is: we are cautious because of evidence and patient safety, not loyalty to industry.

  • We recommend only treatments or tests that are scientifically proven to be safe and effective.

  • NHS and charity organisations must follow regulatory standards and cannot endorse unvalidated products.

  • Our priority is protecting patients from harm, wasted resources, and delays in care.

Being cautious doesn’t mean rejecting innovation. If a new antifungal therapy, dietary approach, or environmental test is genuinely effective, it will be validated through peer-reviewed research — and we will share it.

Until then, our guidance focuses on evidence-based medicine and environmental interventions, because those are proven to help people with aspergillosis.

Key message

Damp and mould can make you unwell — but there is no quick test, no secret biomarker, and no miracle detox that can prove or cure it.
Stick with evidence-based medicine, protect your living environment, and seek support from trustworthy sources.

Save your money, protect your health, and trust science.

by GAtherton

💚 Living With Aspergillus fumigatus and Starting Antifungal Treatment

Question: “I have Aspergillus fumigatus and I’d like to ask a few questions.
After starting antifungal treatment, how long did it take before you noticed improvement or a stop in the bleeding cough?
Has anyone reached a stable condition or full recovery?
Please share your experiences — it would really help to hear from you.” 💚

🌿 A Supportive Note

Many people ask this question when they first begin treatment — and it’s a very normal concern. Aspergillus fumigatus can cause a range of lung problems such as chronic pulmonary aspergillosis (CPA), aspergilloma, or Allergic Bronchopulmonary Aspergillosis (ABPA), and each responds differently to antifungal therapy.

Improvement can take time and patience.
Some notice changes within weeks, while for others, it can take several months before symptoms start to ease or stabilise.

💊 Understanding How Antifungal Treatment Works

Antifungal medicines — such as itraconazole, voriconazole, or posaconazole — don’t destroy Aspergillus overnight.
They work by slowing or stopping fungal growth, allowing the body’s immune system and lung healing processes to gradually take over.

Because these infections are often chronic, the goal is usually to:

  • Control symptoms

  • Prevent further damage

  • Reduce inflammation and flare-ups

  • Stabilise lung function

For most patients, this means aiming for long-term stability rather than complete eradication of the fungus.

⏳ How Long Before You Feel Better?

Every patient is different, but this is a general pattern doctors often see:

Time after starting treatment What you might notice
First few weeks Some reduction in coughing or mucus; fewer night sweats; side effects settling as your body adjusts.
1–3 months Energy may start to improve; less coughing or blood in sputum; breathing slightly easier.
3–6 months Signs of stability — symptoms no longer worsening, CT scans showing improvement, or blood markers (e.g. Aspergillus IgG) falling.
6–12 months Some people achieve remission or long-term stability. For others, antifungal therapy continues as maintenance.

If you have a fungal ball (aspergilloma), improvements are often slower, and sometimes bleeding episodes take longer to settle.

🩸 About Bleeding (Haemoptysis)

Coughing up blood can be one of the most distressing symptoms.
It usually improves once antifungals reduce inflammation, but if bleeding continues:

  • Doctors may prescribe tranexamic acid to help the blood clot more easily.

  • In some cases, embolisation (a targeted procedure to seal a bleeding blood vessel) may be needed.

  • Ongoing bleeding should always be reported — even small amounts — so your team can reassess treatment or check for infection changes.

🫁 Why “Stable” Can Be a Positive Outcome

Although “cure” is possible in some early or mild cases, most people live with aspergillosis as a chronic condition.
With consistent antifungal therapy, airway clearance, and monitoring, many reach a stable stage — where symptoms are minimal, life feels more predictable, and flare-ups are rare.

This stability is a real success.
It means your body and treatment are keeping the infection under control, preventing further lung damage.

💚 Real Experiences

Patients often describe:

  • Energy and breathlessness improving slowly

  • Bleeding stopping after several months

  • A new sense of normality once medication side effects settle

Some take antifungals for a set course (e.g. 6–12 months), while others remain on long-term maintenance to stay stable.
It’s common for treatment to be adjusted based on blood levels, side effects, or new sputum results.

💬 Patient Voices

Many people in our community say they wish they’d known:

  • “Improvement isn’t quick — it’s gradual, but it does come.”

  • “Side effects can be managed — don’t stop without advice.”

  • “It’s okay to ask your team what ‘stable’ looks like for you.”

  • “You’re not alone — others have been through this too.”

🧭 Looking After Yourself Along the Way

  • Keep up airway clearance (physiotherapy, saline nebulisers, or airway devices).

  • Attend regular clinic appointments for blood levels and liver tests.

  • Report side effects early — dose adjustments or switching antifungals often helps.

  • Maintain good nutrition and hydration.

  • Reach out for emotional support. Living with a chronic infection can be mentally exhausting; anxiety and fatigue are common.

💬 We’d Love to Hear From You

If you’ve been through antifungal treatment, please share your story:

  • How long it took before you felt a difference

  • What helped you most

  • How you manage side effects or flare-ups

Your experience could make a real difference to someone who’s just starting this journey. 💚

by GAtherton

💨 Why Chest Infections Keep Coming Back — and What Can Help

Lisa asks:

“Hi, how do you get rid of chest infections? I had one, and the doctors gave me Clarithromycin. It didn’t clear, so they did a sputum test — it showed Haemophilus influenzae. Then I was given Co-trimoxazole, but that didn’t clear it either. The next test still showed it, so now I’m on Amoxicillin. Is this normal? I’m losing hope of it ever going away.”

💬 You’re Not Alone, Lisa

It’s very common for people with aspergillosis, bronchiectasis, or chronic lung disease to find that chest infections take a long time to clear.
Even with the right antibiotics, infections like Haemophilus influenzae can hang on for weeks or even months — but that doesn’t mean treatment isn’t working.

🦠 Why These Infections Keep Coming Back

  • Thick mucus and biofilms:
    In damaged airways, bacteria can hide deep in sticky mucus or biofilms (protective layers). This makes them hard to reach, even with antibiotics.

  • Narrow or scarred airways:
    In bronchiectasis and aspergillosis, parts of the lung don’t drain properly, so infection pockets linger.

  • Reinfection rather than relapse:
    Sometimes, you clear one infection but pick up another of the same type from your own airways later.

  • Inflammation:
    Even when bacteria are gone, airway inflammation can cause ongoing cough and sputum, making it feel as if the infection hasn’t cleared.

💊 Why Doctors Change Antibiotics

Each antibiotic works in a different way.
Your team chooses them based on sputum culture results, which show which antibiotics your bacteria are sensitive to.
It’s quite normal to:

  • Start with a broad antibiotic (e.g. clarithromycin)

  • Switch after sputum results come back

  • Need longer or combination treatment if infection persists

For people with chronic lung conditions, antibiotic courses may last 2–3 weeks, not the usual 5–7 days.

💨 What Can Help You Recover

  • Regular airway clearance:
    Using devices like an Acapella, Aerobika, or chest physiotherapy helps move mucus out of the lungs. This allows antibiotics to reach infection sites better.

  • Stay hydrated to keep mucus thin.

  • Nebulised saline (if prescribed) can help loosen secretions.

  • Avoid skipping doses — consistent antibiotic levels help stop bacteria from regrowing.

  • Regular sputum tests guide your doctors in choosing the next best treatment.

  • See your specialist team if infections return frequently — they might check for fungal infection, resistant bacteria, or airway blockages.

❤️ The Take-Home Message

Yes — it’s quite normal for lung infections like Haemophilus influenzae to need several antibiotics and take time to clear when you have chronic lung disease.
It doesn’t mean your body isn’t fighting — it just means your lungs need a bit more help.
Keep in touch with your specialist nurse or clinic, and don’t lose hope — with good airway care, the right antibiotics, and patience, things usually improve.

by GAtherton

🧬 The Story of Brensocatib: A New Way to Calm Lung Inflammation

What Is Brensocatib?

Brensocatib is a new type of anti-inflammatory medicine being developed to protect the lungs from long-term damage caused by overactive immune cells, especially neutrophils.
It is being tested by the company Insmed in people with bronchiectasis, but it may also help those with aspergillosis and other chronic lung diseases where inflammation is a major problem.

Brensocatib is taken as a once-daily tablet—not an injection.

Why Was It Developed?

In conditions like ABPA (Allergic Bronchopulmonary Aspergillosis) and CPA (Chronic Pulmonary Aspergillosis), inflammation is often persistent.
The lungs attract neutrophils, which are immune cells that normally destroy germs.
However, when too many neutrophils gather, they release enzymes that damage healthy lung tissue, thicken mucus, and make infection easier for fungi and bacteria.

Researchers realised that if they could turn down the destructive part of neutrophil activity—without turning off the immune system completely—they might be able to break the cycle of inflammation and infection.

How Brensocatib Works

Brensocatib blocks a switch inside the bone marrow called DPP1 (dipeptidyl peptidase-1).
DPP1’s job is to “activate” enzymes inside newly formed neutrophils before they enter the bloodstream.

By blocking DPP1, brensocatib stops neutrophils from producing harmful enzymes such as neutrophil elastase.
These neutrophils can still travel to the lungs and fight infection, but they cause less collateral damage.

👉 In short: brensocatib reduces lung injury caused by over-active immune cells, not by suppressing immunity itself.

Not a Biologic – A Different Type of Treatment

It’s important to understand that brensocatib is not a biologic.

Feature Biologic drugs (e.g. mepolizumab, dupilumab) Brensocatib
Made from Complex proteins or antibodies Small chemical molecule
How it’s given Injection or infusion Oral tablet
What it targets Specific immune pathways (e.g. IL-5, IL-4) Enzyme activation in neutrophils
Purpose Block inflammatory signals Reduce tissue-damaging enzymes
Typical use Severe asthma, ABPA, autoimmune diseases Bronchiectasis, chronic airway inflammation

So, while biologics act by targeting immune messengers in the bloodstream, brensocatib works deeper—at the level of neutrophil development.
The two approaches are different but potentially complementary.
Some people in future may benefit from a combination, depending on their pattern of inflammation.

The Development Story

  • Early research (2010s): Scientists found that blocking DPP1 prevented lung injury in animal studies.

  • Insmed’s discovery: Brensocatib was developed as an oral, selective DPP1 inhibitor.

  • Phase 2 WILLOW trial (2020): In people with bronchiectasis, brensocatib significantly reduced flare-ups and lowered airway inflammation.

  • Phase 3 ASPEN trial (2022–2025): A large international study now nearing completion; results are expected soon.

If successful, brensocatib could become the first approved DPP1 inhibitor for long-term inflammatory lung disease.

Why This Matters for Aspergillosis Patients

People living with aspergillosis often also have bronchiectasis, where inflammation causes persistent mucus, infection, and breathlessness.
Current treatments such as steroids, antifungals, and biologics can help, but each has limits.

Brensocatib could:

  • Reduce airway inflammation without steroid side-effects

  • Protect lung tissue from further damage

  • Possibly lower the number of flare-ups or infections

  • Work safely alongside antifungals or biologics

It represents a new way of calming inflammation—by modifying neutrophil behaviour rather than blocking the immune system.

What Happens Next

The ASPEN Phase 3 results are expected soon. If positive, Insmed plans to apply for approval in the UK, EU, and USA.
Researchers are also studying brensocatib in:

  • COPD (Chronic Obstructive Pulmonary Disease)

  • Cystic fibrosis

  • Nontuberculous mycobacterial (NTM) infections

If licensed, it could mark the first new oral anti-inflammatory class for chronic lung disease in decades.

Key Take-Home Messages

  • Brensocatib reduces harmful lung inflammation by blocking the enzyme DPP1.

  • It is a small-molecule tablet, not a biologic injection.

  • It aims to protect the lungs by preventing damage from overactive neutrophils.

  • It may offer a steroid-sparing option for chronic airway diseases like bronchiectasis and aspergillosis.

  • It’s currently in final clinical trials, with results expected soon.

💬 Find Out More

by GAtherton

🫁 “Lung Flush” (Bronchoalveolar Lavage) in ABPA – What It Is and Why It Brings Only Short-Term Relief

A lung flush (also called a bronchoalveolar lavage, or BAL) isn’t a regular treatment for Allergic Bronchopulmonary Aspergillosis (ABPA), but it’s sometimes used selectively in NHS hospitals.

💧 What Happens During a Lung Flush

It’s done during a bronchoscopy, where a thin, flexible tube is passed through the nose or mouth into the lungs.
A small amount of sterile saline is washed into part of the lung and then gently suctioned back out.
The fluid is tested for:

  • Aspergillus growth or DNA

  • Other infections (bacteria, fungi, viruses)

  • Signs of inflammation or allergic activity

You’re given local anaesthetic and light sedation, so you stay comfortable but sleepy. Most people go home the same day.

🧪 Main Purpose – Diagnosis

In most ABPA cases, a lavage is done to find out what’s causing symptoms – whether they’re due to Aspergillus, another infection, or ongoing inflammation.
The results help doctors fine-tune treatment, such as adjusting antifungal doses or deciding if a biologic drug might help.

🫁 Sometimes Used to Clear Mucus

In certain situations – especially when thick mucus plugs are blocking airways or causing part of a lung to collapse – doctors may use lavage as a therapeutic “flush.”
This can wash out sticky secretions and temporarily improve airflow, helping physiotherapy and medication work more effectively.

It’s usually a short, day-case procedure, and most people feel back to normal after a day or two.

⚠️ Why It’s Only Short-Term Relief

Although lavage can clear mucus, ABPA is caused by an allergic immune reaction, not by the mucus itself.
Unless that reaction is controlled with:

  • Corticosteroids (to reduce inflammation),

  • Antifungal drugs (to lower the fungal load), or

  • Biologic injections (to block allergy pathways),

…the lungs will continue to produce thick, sticky mucus, which can re-accumulate within days or weeks.
So while a “lung flush” can make breathing easier in the short term, the effect is temporary – like clearing a blocked drain while the tap is still running.

⚠️ Risks and After-Effects

A bronchoscopy with lavage is generally safe, but it is still an invasive procedure. Possible effects include:

  • Temporary sore throat, cough, or hoarseness (common)

  • Mild bleeding or streaks of blood in sputum for a short time

  • Low oxygen levels during or after the procedure (monitored carefully)

  • Chest tightness, infection, or fever – uncommon but possible

  • Bronchospasm (airway narrowing) in people with very sensitive lungs, which is why it’s done in a hospital with respiratory support available

Because of these small but real risks, the NHS uses lavage only when the benefits outweigh the downsides – for example, when mucus is causing serious blockage or when test results will change management.

💬 In Summary

A “lung flush” can temporarily clear mucus and ease breathing, but it doesn’t stop ABPA’s underlying allergic inflammation.
The mucus often returns unless that inflammation is brought under control with long-term medical treatment.
It’s a useful tool when needed, but not something done regularly or lightly.

by GAtherton